Thursday, 23 December 2021

BioLargo’s PFAS Removal System Achieves Total Elimination of Multiple PFAS Compounds in Testing with Client Water

Westminster, CA – December 23, 2021 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, announced that its Aqueous Electrostatic Concentrator (AEC) has been proven to eliminate multiple per- and polyfluoroalkyl substance (PFAS) compounds from water provided by a large municipality in Southern California.

Found in water all over the world, PFAS are a group of chemicals generated by industrial operations that have been linked to adverse health effects. They are subject to escalating regulatory action by the Biden Administration and the EPA due to their inability to break down naturally in the environment and their impacts on human health. Also known as “forever chemicals”, PFAS have been linked to cancer, developmental delays, hormone disorders, and more. According to Washington DC based Environmental Working Group, PFAS has been founding in water in over 2,800 locations in the United States.

Previously, the company reported that the AEC had been shown to reduce the levels of several PFAS compounds present in water provided by the prospective municipal client to below State and Federal standards. These new results prove that the AEC has removed multiple PFAS compounds to below the limit of quantification (i.e., functionally eliminated) following optimization of the AEC’s membranes and contact time.

Randall Moore, President of BioLargo Engineering, Science & Technologies commented, “These results confirm not only that the AEC can deliver virtually total elimination of PFAS from contaminated drinking water, but that the technology can, with relative ease, be fine-tuned to achieve varying levels of treatment performance as prescribed by a client’s own treatment goals and regulatory needs.”

Tonya Chandler, Director of Strategic Marketing and Business Development at BioLargo, commented, “These results show that the AEC is an effective solution for customers seeking PFAS water treatment and removal, and will be integral as we advance to commercial trials and first sales of the technology. Our AEC system is capable of total PFAS elimination while generating less than 1/1000 the volume of PFAS-laden waste product compared to carbon filtration, the most common solution in the market today. No one wants to trade one environmental disaster for another, and the AEC helps avoid the trailing environmental impact and significant cost associated with disposal of PFAS-laden carbon.”

To learn more about BioLargo’s AEC technology, visit https://www.biolargoengineering.com/biolargo-aec/.

 

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our peer-reviewed scientific approach allows us to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

 

Thursday, 16 December 2021

BioLargo, Inc. Discusses Development and Scale-Up of Its PFAS Treatment Technology and 2022 Commercial Plans With The Stock Day Podcast (BLGO)

Source: Stock Day Media (https://stockdaymedia.com/biolargo-inc-discusses-development-and-scale-up-of-its-pfas-treatment-technology-and-2022-commercial-plans-with-the-stock-day-podcast-blgo/

Phoenix, Arizona–(Newsfile Corp. – December 16, 2021) – The Stock Day Podcast welcomed BioLargo, Inc. (OTCQB: BLGO), a company that invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, wastewater treatment, and industrial odor and VOC control. President and CEO of BioLargo, Dennis P. Calvert, joined Stock Day host Everett Jolly for an interview.

Jolly began by asking about BioLargo’s consumer products strategic partnership with Ikigai Holdings. “Ikigai is a company that is focused on launching consumer products,” explained Calvert. “The partners at Ikigai have launched at least five blockbuster products in their careers,” he said, adding that they are “experts in the art of launching products that can build into a national brand.” He added, “We have bargained to be the supply chain partner. So, we’re wholesaling our product, earning a royalty on the technology, and then participating in a minority way on the exit.”

Jolly then asked about the progress of BioLargo’s Garratt-Callahan partnership. “Garratt-Callahan is the largest privately held water [treatment] company in America,” said Calvert. “We joined them as a technical expert to bring forth engineering and science to develop a product according to a design that they had created,” he explained. “That product is being tested now,” said Calvert. “We’re hoping to launch very early in 2022.”

The conversation then turned to the commercialization of BioLargo’s technology that eliminates per- and polyfluoroalkyl substances (PFAS), a class of water contaminants of rising concern because of their ubiquity in water around the world and their long-term health effects. “The Biden administration has listed [PFAS] as one of the top environmental issues of the decade,” said Calvert. “We have a device and expertise that provides selective extraction [of PFAS] … [It generates] 1/1000 the waste that’s created for disposal of the competition.”

The company hopes to get its PFAS treatment technology, called the Aqueous Electrostatic Concentrator, commercialized in 2022 in part by partnering with established players in the water treatment industry. “These projects could range [from] half a million all the way up to [the] fifteen million dollar range,” Calvert explained. “I think this is a huge opportunity for BioLargo to create value for our shareholders, so we are very excited.”

To hear Dennis Calvert’s entire interview, follow the link to the podcast here: https://audioboom.com/posts/7998255-biolargo-inc-discusses-development-and-scale-up-of-its-pfas-treatment-technology-and-2022-comme

Investors Hangout is a proud sponsor of “Stock Day,” and Stock Day Media encourages listeners to visit the company’s message board at https://investorshangout.com/

About BioLargo, Inc.

BioLargo, Inc. (OTCQB: BLGO) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our peer-reviewed scientific approach allows us to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

About The “Stock Day” Podcast

Founded in 2013, Stock Day is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Stock Day provides companies with customized solutions to their news distribution in both national and international media outlets. The Stock Day Podcast is the number one radio show of its kind in America.

SOURCE:

Stock Day Media
(602) 821-1102

Wednesday, 8 December 2021

BioLargo Begins Next Step in Preparing Garratt-Callahan Minimal Liquid Discharge System for Commercial Launch


Westminster, CA – December 8, 2021 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, has taken the next step to commercialize the new wastewater treatment technology, called a “minimal liquid discharge” system, that it designed and manufactured for Garratt-Callahan, a century-old national water treatment company. In this stage, BioLargo engineers will process contaminated water with a full-scale prototype of the new technology to verify its treatment efficacy and durability. Once this stage is completed successfully, sales can begin to Garratt-Callahan customers.

The new wastewater treatment system is based on Garratt-Callahan’s “minimal liquid discharge (MLD)” technology, which reduces the volume of wastewater discharge from industrial facilities, saving customers disposal fees while reducing strain on sewage infrastructure and the environment. The engineers will start by treating simulated industrial wastewater to optimize the technology’s performance, then will finish by treating actual industrial wastewater provided by Garratt-Callahan customers.

“We are excited to be working with Garratt-Callahan to launch this product because of their pedigree of innovation and integrity in the water industry. Their focus on developing technologies that reduce freshwater usage aligns with our values of focusing on sustainable solutions above all else,” said Randall Moore, President of BioLargo Engineering, Science & Technologies.

Tonya Chandler, BioLargo’s Director of Strategic Marketing and Business Development, said, “This project highlights our capabilities to serve customers as an innovator and solutions provider in wastewater treatment. We helped scale the design of the MLD system, we manufactured it, and now we’re testing it in our in-house water lab to validate its performance before it ships to customers.

 

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our peer-reviewed scientific approach allows us to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

Wednesday, 1 December 2021

BioLargo Signs Manufacturer’s Representative Agreement with ICS Group for its Innovative Water Treatment Technologies

Westminster, CA – December 1, 2021 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, announced it has signed a manufacturer’s representative agreement with the ICS Group, a premier manufacturer’s representative company that has provided innovative wastewater, energy management, and renewable energy technology solutions to municipal and industrial clients, primarily in the Midwestern United States, since 2009. As this is the first manufacturer’s representative for BioLargo’s innovative water treatment technologies, this represents an important step toward building a commercial network for their sale and distribution.

ICS Group has been tasked to sell BioLargo’s two proprietary water treatment technologies, the Advanced Oxidation System (AOS) energy-efficient wastewater disinfection, micropollutant removal, and water reuse technology, and the Aqueous Electrostatic Concentrator (AEC) technology for affordable, low-waste treatment of PFAS-contaminated water, as well as other water and wastewater treatment equipment that BioLargo offers as an authorized reseller of other manufacturers. The ICS Group will also sell BioLargo’s PFAS Testing Program service, which offers fast and affordable testing of clients’ PFAS-contaminated water for the purposes of treatment system optimization, and CupriDyne Clean, the company’s patented odor and volatile organic compound (VOC) control product.

Paul Nygaard, President of ICS Group, said, “We specialize in innovative water and wastewater process technologies. We always strive to bring cutting edge technologies to the market that help our clients achieve challenging treatment objectives. BioLargo’s unique technology platforms definitely bring that capability to our treatment solutions.”   

“ICS Group has a reputation of outstanding customer service, making them the perfect choice to be our first manufacturer’s representative for our technologies. They’re also known for taking on new and innovative technologies that address unmet needs in the water treatment marketplace,” said Tonya Chandler, BioLargo’s Director of Strategic Marketing and Business Development. “We intend to add more sales representatives soon and hope they will be as great a fit as the ICS Group to our values.”

 

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our peer-reviewed scientific approach allows us to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

Tuesday, 30 November 2021

BioLargo Strategic Partnership with Ikigai to Launch New Consumer Product

Direct to Consumer Test Marketing is Successful

Westminster, CA – November 30, 2021 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, announced that it had received a “go decision” from its strategic partner, Ikigai Holdings, LLC, following positive results from the test-marketing phase of a new pet odor control product based on BioLargo’s proprietary technology, branded “POOPH”. The “go decision” indicates Ikigai’s intent to expand television advertising with the goal to launch the product into big-box retailers, and formalizes their exclusive license to the product.

Ikigai Holdings, LLC is comprised of veteran consumer product executives with experience launching and growing multiple blockbuster consumer products. Ikigai developed the “POOPH” brand, created television commercials and other advertising content, and then conducted a television direct-response test marketing campaign to assess the probability that the product would be a commercial success.

Jane Pak, Ikigai CEO, commented, “Early feedback from the test marketing of the POOPH product has been phenomenal. We have placed our initial purchase orders to support an expanded marketing campaign that will begin right after Christmas to gather additional data which will be instrumental in supporting accelerated consumer sales and establishing a strong transition from direct-to-consumer into retail. We are thrilled to see validation that POOPH can disrupt the highly established category of pet odor control products, and with these results, we are already thinking about more products based on BioLargo’s technology.”

BioLargo CEO Dennis P. Calvert commented, “Ikigai will purchase the POOPH products from us, and in addition, we receive a royalty on sales. They will finance and manage product roll-out, distribution, and marketing. We are excited about the potential for this partnership to create significant new revenue for both partners. The team at Ikigai is amazing!”

  

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our peer-reviewed scientific approach allows us to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

 

Monday, 15 November 2021

BioLargo’s Third Quarterly Report for 2021 Details Progress of PFAS Technology Commercialization and Ongoing Partnerships













Westminster, CA – November 16, 2021 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, filed its latest Quarterly Report on Form 10-Q with the SEC yesterday (www.biolargo.com/sec-filings). The company has summarized some of the most important points from the report below.

The company is holding an investor webcast on Wednesday, November 17, 2021, at 8:00 am Pacific / 11:00 am Eastern, at the following link, open to the public: https://www.webcaster4.com/Webcast/Page/2448/43712   

Dennis P. Calvert, President and CEO of BioLargo said, “In this quarter, our engineering group broke its all-time revenue record. We began the first step of the multi-phase commercial launch of our PFAS treatment technology and confirmed the technology works with real client-provided water, achieving results that meet government standards. Our work at the Montreal wastewater treatment plant proved that our other water treatment technology, the AOS, is highly effective at removing pharmaceuticals from wastewater compared to existing technologies. Our consolidated revenue grew, and we shrank our net loss.”

He continued, “The hard work we’ve done to prepare to launch products with Garratt-Callahan is paying off. We will be doing commercial testing with water from multiple prospective Garratt-Callahan customers in the coming weeks. We’re on track to secure first customer orders for this product in the first quarter of 2022.”

Financial highlights from the 10-Q:

  • Consolidated revenue for the three months ended September 30, 2021, was $712,000, a 7% increase compared to the prior year’s period. Revenue generated by BioLargo’s engineering division increased by 73% compared to last year’s period, and 92% as compared with the second quarter of 2021.
  • The company’s net loss during the quarter was reduced to $1.3 million, down from $2.1 million in the same period of the prior year. The improvement in the company’s net loss is due in large part to a significant reduction in interest expenses due to retired debt over the past year.

Commercial, operational, and R&D highlights:

  • First PFAS testing successful – testing of water provided by the company’s first prospective PFAS treatment client, a large municipality in southern California, has confirmed that BioLargo’s PFAS treatment technology can remove all PFAS compounds of regulatory interest to below State and Federal standards. Additional testing to optimize the AEC underway. Testing with our second prospective client’s water is slated to begin next week.
  • Garratt-Callahan prototype unit completed – as part of BioLargo’s partnership with the water treatment company Garratt-Callahan, BioLargo has just finished building a full-scale prototype unit of their patented “minimal liquid discharge” system for testing on client-provided water. The technology is designed to reduce industrial wastewater discharge and fees associated with discharge. BioLargo engineers will be testing the system’s performance soon, and management targets first sales in the early 2022.
  • Engineers break revenue record – BioLargo’s engineering group’s quarter-over-quarter revenue grew by 92% in Q3, having completed over half the work for the $1.2 million worth of engineering projects announced in June of 2021, the remainder of which is expected to complete in the next six months.
  • 3-year exclusive chemistry supply contract – BioLargo’s subsidiary ONM Environmental secured an exclusive three-year CupriDyne Clean supply contract with a large municipality in Southern California.
  • TV test marketing shows promising results – a quote from Ikigai Holdings President Jane Pak on the new pet odor product based on BioLargo’s technology: “The Ikigai team is pleased to see the product get a positive response early in the market testing period. The next three weeks of media placement will be critical to predicting probability of volume and velocity, but in our first week of placement we are already seeing some very promising results.”
  • AOS pilot confirms performance – the AOS pilot project in Montreal, Quebec, has confirmed that the AOS is highly effective at removing pharmaceutical micropollutants from municipal wastewater in a real-world setting, faster and using less electricity than major incumbent technologies, making it an attractive product for municipal wastewater treatment customers. A video about this pilot is available here: https://biolargo.blogspot.com/2021/09/biolargo-aos-water-treatment-technology.html
  • Peer-reviewed paper confirms AOS breakthrough – a peer-reviewed scientific paper was published confirming that the AOS generates highly energetic iodine molecules, helping explain why the AOS is a powerful, efficient, and novel water treatment technology. The article, and a summary thereof, can be accessed here: https://biolargo.blogspot.com/2021/09/peer-reviewed-paper-explains.html

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our peer-reviewed scientific approach allows us to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

BioLargo Q3 2021 Earnings Results Webcast and Conference Call on Wednesday, November 17, 2021 - 11:00 AM Eastern Time

Westminster, CA – November 15, 2021 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable technologies and full-service environmental engineering company, announced it will host an investor webcast and conference call on Wednesday, November 17, 2021, at 8:00 am PST / 11:00 am EST. The webcast and conference call, which is open to the public, will be held to review the company’s financial results, discuss recent commercial milestones, and conduct a question-and-answer session.

The webcast and teleconference replay will be made available on the Investor Relations section of BioLargo’s website at biolargo.com/investor-relations. To listen to a live broadcast, go to the site at least 15 minutes prior to the scheduled start time to register, download, and install any necessary audio video software.

 

To participate in the live webcast and teleconference:

Webcast Link:

https://www.webcaster4.com/Webcast/Page/2448/43712

Teleconference Domestic:

888-506-0062

Teleconference International:

973-528-0011

 

To watch or listen to a replay of the webcast or teleconference:

 

Webcast Replay Expiration:

Wednesday, November 16, 2022

Teleconference Replay Expiration:

Tuesday, December 1, 2022

Teleconference Replay Domestic:

877-481-4010

Teleconference Replay International:

919-882-2331

Replay Passcode:

43712

 

 About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our peer-reviewed scientific approach allows us to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

 

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.